{
    "ticker": "GNLX",
    "name": "Genelux Corporation",
    "description": "Genelux Corporation is a biotechnology company focused on developing innovative therapies for cancer treatment. Established in 2001, Genelux is dedicated to harnessing the power of oncolytic virus technology, which utilizes genetically modified viruses to selectively target and destroy cancer cells while sparing normal tissues. The company's lead product candidate, OLX-104, is an oncolytic virus therapy designed for the treatment of various solid tumors. Genelux aims to revolutionize cancer treatment by offering a new class of therapeutics that can work synergistically with existing treatments, potentially improving patient outcomes and quality of life. With a robust pipeline of product candidates in various stages of clinical development, Genelux is poised to make significant contributions to the field of oncology. The company is headquartered in San Diego, California, and collaborates with leading research institutions and hospitals to advance its clinical programs. Overall, Genelux is committed to providing hope to cancer patients through cutting-edge science and innovative therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2001",
    "website": "https://www.genelux.com",
    "ceo": "Dr. K. R. (Randy) Pritchard",
    "social_media": {
        "twitter": "https://twitter.com/genelux",
        "linkedin": "https://www.linkedin.com/company/genelux-corporation/"
    },
    "investor_relations": "https://www.genelux.com/investor-relations",
    "key_executives": [
        {
            "name": "Dr. K. R. (Randy) Pritchard",
            "position": "CEO"
        },
        {
            "name": "Dr. Tamer Elsayed",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncolytic Virus Therapies",
            "products": [
                "OLX-104"
            ]
        }
    ],
    "seo": {
        "meta_title": "Genelux Corporation | Innovative Cancer Therapies",
        "meta_description": "Genelux Corporation is a leader in oncolytic virus technology, developing novel cancer therapies to improve patient outcomes. Explore our innovative pipeline.",
        "keywords": [
            "Genelux",
            "Oncolytic Virus",
            "Cancer Therapy",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Genelux known for?",
            "answer": "Genelux is known for developing innovative oncolytic virus therapies for cancer treatment."
        },
        {
            "question": "Who is the CEO of Genelux?",
            "answer": "Dr. K. R. (Randy) Pritchard is the CEO of Genelux Corporation."
        },
        {
            "question": "Where is Genelux headquartered?",
            "answer": "Genelux is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Genelux's lead product candidate?",
            "answer": "Genelux's lead product candidate is OLX-104, an oncolytic virus therapy for solid tumors."
        },
        {
            "question": "When was Genelux founded?",
            "answer": "Genelux was founded in 2001."
        }
    ],
    "competitors": [
        "PFE",
        "AMGN",
        "BMY"
    ],
    "related_stocks": [
        "MRNA",
        "NVAX",
        "REGN",
        "GILD"
    ]
}